Trials / Recruiting
RecruitingNCT06576401
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects
A Phase1 Study to Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
In this study, a single dose of \[14C\] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral \[14C\] HDM002.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] HDM1002 | Administered orally |
Timeline
- Start date
- 2024-08-27
- Primary completion
- 2024-10-01
- Completion
- 2024-12-01
- First posted
- 2024-08-28
- Last updated
- 2024-09-04
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06576401. Inclusion in this directory is not an endorsement.